Intrommune Therapeutics is a biotechnology company developing patient-friendly therapies for the treatment of food allergies. The company’s oral mucosal immunotherapy (OMIT) platform is based on the well-accepted principles of allergy immunotherapy. Immunotherapeutic agents are regularly administered to areas of the oral cavity with the highest likelihood of decreasing allergy symptoms, gradually desensitizing the immune system to specific foods.
Get in touch
- Business industry:Biotechnology
- Number of employees:Fewer than 10
- Business type:B2C
- Years in business:5-9
- Last funding type:Series A
Actual investments will be updated in near time